Amarin Corp Plc (AMRN)

[ziploc_1]

One...when you have excess inventory, you need to have a sale...This is what KM may been preparing us for when he mentioned an authorized generic Vascepa during the Q3 C.C.

After depleting all the Vascepa in its inventory, Amarin could then cease selling Vascepa ...and replace Vascepa with MND-2119.

Before executing this strategy, Amarin would need to seek to have MND-2119 approved by the FDA, which I hope will occur ASAP.

MND-2119 is already approved in Japan and is currently being marketed there...With the safety and effectiveness of EPA, in reducing CVD, having been already demonstrated in millions of patients around the world. I would anticipate a positive result for this superior formulation of EPA.